Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Sun, Jingwei, Chen, Kun, Ma, Peiwen, Lei, Qi, Xing, Shujun, Cao, Zhongzheng, Sun, Shujun, Yu, Zicheng, Liu, Yarong, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194199/
https://www.ncbi.nlm.nih.gov/pubmed/34112147
http://dx.doi.org/10.1186/s12916-021-02006-4
_version_ 1783706370845966336
author Wang, Shuhang
Sun, Jingwei
Chen, Kun
Ma, Peiwen
Lei, Qi
Xing, Shujun
Cao, Zhongzheng
Sun, Shujun
Yu, Zicheng
Liu, Yarong
Li, Ning
author_facet Wang, Shuhang
Sun, Jingwei
Chen, Kun
Ma, Peiwen
Lei, Qi
Xing, Shujun
Cao, Zhongzheng
Sun, Shujun
Yu, Zicheng
Liu, Yarong
Li, Ning
author_sort Wang, Shuhang
collection PubMed
description Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed.
format Online
Article
Text
id pubmed-8194199
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81941992021-06-15 Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors Wang, Shuhang Sun, Jingwei Chen, Kun Ma, Peiwen Lei, Qi Xing, Shujun Cao, Zhongzheng Sun, Shujun Yu, Zicheng Liu, Yarong Li, Ning BMC Med Review Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed. BioMed Central 2021-06-11 /pmc/articles/PMC8194199/ /pubmed/34112147 http://dx.doi.org/10.1186/s12916-021-02006-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Wang, Shuhang
Sun, Jingwei
Chen, Kun
Ma, Peiwen
Lei, Qi
Xing, Shujun
Cao, Zhongzheng
Sun, Shujun
Yu, Zicheng
Liu, Yarong
Li, Ning
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title_full Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title_fullStr Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title_full_unstemmed Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title_short Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
title_sort perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194199/
https://www.ncbi.nlm.nih.gov/pubmed/34112147
http://dx.doi.org/10.1186/s12916-021-02006-4
work_keys_str_mv AT wangshuhang perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT sunjingwei perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT chenkun perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT mapeiwen perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT leiqi perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT xingshujun perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT caozhongzheng perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT sunshujun perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT yuzicheng perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT liuyarong perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors
AT lining perspectivesoftumorinfiltratinglymphocytetreatmentinsolidtumors

Ejemplares similares